Dr. Clay Siegall is a legend when it comes to targeted cancer therapies. The founder and CEO of the Seattle, Washington based biotechnology company Seattle Genetics, Dr. Siegall is the driving force behind some of the most effective cancer treatment therapies and drugs being used today. His company specializes in developing targeted therapy drugs that substantially improve patient healing and mortality rates. Since he founded Seattle Genetics in 1998, the firm created the first antibody drug conjugate to get FDA approval. That drug now has a number of approved indications and is widely used.
Under Dr. Siegall’s leadership Seattle Genetics is now at the top of the targeted cancer therapy industry. Long interested in medicine, Dr. Siegall became involved in researching better cancer treatments when he saw how a family member was ravished by the cancer treatment they received. Through hard work and great focus the company has been able to develop a product pipeline that includes over 20 drugs with the potential to improve treatment outcomes for cancer patients. Dr. Siegall has also been able to establish strategic partnerships with Pfizer, Genentech, Bayer and several other companies.
As an undergraduate Dr. Clay Siegall attended the University of Maryland where he earned a B.S. in Zoology. He then graduated from George Washington University where he got his Ph.D in genetics. He then went on to work with some of the top companies involved in cancer research. They include the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and the National Institutes of rHealth. He’s also on the board of Washington Roundtable, Alder BioPharmaceuticals and
The recipient of numerous accolades and awards, Dr. Siegall was voted University of Maryland 2013 Alumnus of the Year and received the 2012 Pacific Northwest ‘Entrepreneur of the Year’ award from Ernst & Young. A prolific writer, Dr. Siegall has had pieces published in over 70 publication. Plus Clay Siegall also holds 15 patents. Due to his passion and seemingly unending fundraising efforts, Dr. Siegall has been able to tap into public and private sources and raise more than $1.2 billion for Seattle Genetics.